3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Rectal Neoplasms
2
Melanoma
2
Triple Negative Breast Neoplasms
1
Sarcoma, Kaposi
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Meningioma
1
Lymphoma, Large B-Cell, Diffuse
1
Liver Neoplasms
1
Glioma
1
Ependymoma
1
Differentiated Thyroid Cancer
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Acquired Immunodeficiency Syndrome
1
AIDS-related Kaposi sarcoma
1
Interventions
pembrolizumab
11
epacadostat
2
Paclitaxel
2
spartalizumab
1
ribociclib
1
Surgical Procedures, Operative
1
Saline Solution
1
Radiosurgery
1
Prednisone
1
Pemetrexed
1
Nivolumab
1
Immunotherapy
1
Gemcitabine
1
Docetaxel
1
Dexamethasone
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
Axitinib
1
AZD 6244
1
2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
AZD 6244
×
Clear all
NCT03833427
2024-11-07
MK-5618-001
Merck Sharp & Dohme LLC
Phase 1
Terminated
32 enrolled
17 charts